is a summer programme that has been hosted by the University of Warwick and The Alan Turing Institute for the last two years, and will this summer, 2021, be delivered by University of Warwick in collaboration with Ludwig Maximillian University (Munich) under the DSSGx UK chapter of the DSSG Foundation.
DSSG is the brainchild of Rayid Ghani, former Chief Scientist for President Obama, and continues to be run in the US at Carnegie Mellon University. Participants are trained over the summer, and work on data science projects with not-for-profit organisations and governmental bodies, helping them leverage their data to improve their services, interventions and outreach.
[December 28, 2020]
iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer
BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) iBio, Inc. (NYSEA:IBIO) (âiBioâ or the âCompanyâ), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (âCSOâ), effective January 18, 2020.
âWe are thrilled to have Dr. Brenner join our team,â said Tom Isett, Chairman & CEO of iBio. âGiven his prior experience leading organizations with novel protein expression platforms to build proprietary product pipelines, Dr. Brenner should be uniquely suited to assist iBio with a similar transformation. Notably, he also brings a track-record of effective new target search and evaluation, as well as establishing productive collaborations.â
MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson s Disease
MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson s Disease (PD). Anle138b is a disease-modifying treatment option for synucleinopathies, such as Multiple System Atrophy (MSA) and PD.
The short-term Phase 1b study with PD patients will be conducted by Quotient Sciences in Nottingham, UK, supported by the Neurology Department of Nottingham University Hospital. The study s primary endpoints include safety, tolerability and pharmacokinetics of anle138b in PD patients in order to establish the optimal dosing scheme for future long-term efficacy trials. The trial is supported by a grant of USD 1.4 million from The Michael J. Fox Foundation for Parkinson s Research.